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Purpose. We analyzed our experience with the phenox clot retriever as part of a multimodal mechanical thrombectomy (MTE)
approach in acute ischemic stroke. Methods. 56 patients were treated by MTE with the phenox clot retriever alone or in
combination with other modalities. Results. Overall we achieved TICI 2b/3 reperfusion rates of 61,9%. In multimodally treated
patients we achieved reperfusion rates of 72,8%. There were 3 (5,5%) severe adverse events, all symptomatic intracranial hemor-
rhages. The mean angio to reperfusion times (ART) were 74 minutes for phenox-only procedures and 51 minutes for multimodal
procedures. A chronological analysis showed a reduction of ART from 70,5 to 49,4 minutes and an increase of TICI 2b/3
recanalizations from 53,8% to 81,8%. Throughout the observation period there was a signiﬁcant shift towards multimodal
procedureswithsimultaneousincreaseofTICI2b/3reperfusions.Botheﬀectsarepartiallyattributabletoourinstitutionallearning
curve. NIHSS improvement could be seen in 54% (n = 28) overall and in 73% (n = 15) of MCA recanalizations. Conclusions.T h e
phenox clot retriever is a safe and eﬀective tool for MTE in acute stroke patients, with faster and better reperfusion results when
used as part of a multimodal strategy. Clinical improvement is more frequent in MCA recanalizations.
1.Introduction
After the large intravenous thrombolysis trials have shown
thattheeﬀectivenessofIVrTPAislimitedespeciallyinsevere
stroke due to large vessel occlusion, mechanical thrombec-
tomy (MTE) has become the focus of a number of trials
leading to the approval of dedicated thrombectomy systems
such as the Merci retriever and the Penumbra aspiration
thrombectomy system [1–3]. In addition to FDA-approved
systems, a number of MTE systems have become available
under CE mark over the past 3 years. One of these systems is
the phenox clot retriever (phenox GmbH, Bochum, Ger-
many). Licensed under CE mark in November, 2006, it
essentially resembles a microbrush that is delivered and re-
leased through a microcatheter and then withdrawn into an
aspiration catheter—either guiding or distal access. Available
in three diﬀerent sizes, it can be used in vessel diameters
b e t w e e n1a n d6m m .B yd e s i g n ,i to ﬀers the unique possi-
bilitytousetwodevicessimultaneously,forexample,incases
of a bifurcation occlusion. In this retrospective study, we
analyzedourexperiencewiththephenoxclotretrieveraspart
of a multimodal thrombectomy approach in acute ischemic
stroke.
2.MaterialandMethods
56 patients with acute ischemic stroke in the anterior and/or
posterior circulation were treated with the Phenox clot re-
triever as the sole device or as part of a multimodality strat-
egy in combination with other devices between 01/2007 and2 The Scientiﬁc World Journal
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Figure 1: Schematic drawing of the phenox clot retriever ((a) pCR) and the phenox clot retriever cage ((b) CRC).
08/2010. Treatment was initiated within 6 hours of symptom
onset for the anterior circulation and 8 hours for the pos-
terior circulation. Neurological evaluation (NIHSS, mRS)
was performed on admission and at discharge. All patients
underwent CT and CTA on admission to rule out hemor-
rhage and to evaluate vessel occlusion. Unenhanced CT was
repeated 18h later (±6h) and at discharge.
According to institutional guidelines, all patients who
presented with symptom onset ≤3h due to large artery oc-
clusion received IV rtPA immediately after the CT scan while
being transferred to our angiography suite for subsequent
MTE. All except one procedures were performed under
general anaesthesia and were carried out by a constant team
of three neuroradiologists. IV lysis was stopped when the
guiding catheter was positioned. If necessary, the remaining
dose, up to a maximum of 0,9mg/kg bodyweight and a total
of 90mg, was administered i.a. via a microcatheter. In case
of contraindications against IV lysis or symptom onset ≥3h,
MTE was performed without adjunctive ﬁbrinolysis. For the
analysis, all patients treated with the phenox clot retriever
alone or in combination with another thrombectomy/aspi-
ration devices and/or ia lytics were selected from our institu-
tional database of more than 180 endovascular treatments of
ischemic stroke.
The Phenox Clot Retriever (pCR, phenox, Bochum, Ger-
many) consists of a ﬂexible nitinol/platinum core wire sur-
rounded by perpendicularly oriented polyamide microﬁla-
ments. These form a conical shape with increasing diameter
towards the distal end covering 3 diﬀerent sizes ranging
from 1 to 3mm proximally and from 2 to 5mm distally.
The smallest is 10mm in length and is introduced through
a 0.021   microcatheter, while the two larger versions are
20mm in length and require a 0.027   catheter (Figure 1).
The2/4mmand3/5mmarealsoavailablewithanitinolcage
attached to the proximal marker that should help to central-
ize the device within the vessel and also allow for enhanced
thrombectomy (CRC, clot retriever cage) (Figure 1). All phe-
nox retrievers should be deployed distal to the thrombus
and then slowly withdrawn under constant aspirating on the
guiding catheter by means of a 50cc syringe.
Because of their backwards-oriented ﬁlaments that make
resheathing impossible, both pCR and CRC retrievers are
single use. Therefore, the maximum number of unsuccessful
attempts with the ﬁrst type of device was three. Thereafter,
we pursued an escalative strategy with a diﬀerent device.
Besides pCR and CRC, we used the Merci retriever (L series),
and the Penumbra aspiration system, percutaneous translu-
minal angioplasty (PTA) with the Ryujin balloon catheter,
permanent or temporary stenting with the Solitairestent and
the Enterprisestent, the Catch system, and a microsnare. The
order of devices within multimodal treatment varied.
Recanalization and reperfusion success were rated on
pre- and postprocedural angiograms according to the
Thrombolysis in Myocardial/Cerebral Infarction (TIMI and
TICI)gradingsystem[4].TICIIIbandIIIwereaccountedfor
as a potential beneﬁcial reperfusion results. Times measured
and documented included symptom onset to groin puncture
(time to angio), onset to ﬁrst reperfusion of TICI 2a or better
(time to reperfusion) groin puncture to ﬁrst reperfusion
(angio to reperfusion), and groin puncture until the end of
the procedure.
Clinically signiﬁcant procedural adverse events (PAE)
and symptomatic intracranial haemorrhage (sICH) were de-
ﬁned by a CT scan within 24h posttreatment and an increase
on the NIHSS of 4 or more points. Clinical improvement/de-
terioration regarding the early outcome was deﬁned as a
pre-/post-NIHSS diﬀerence of 4 or more points and any dif-
ference of the mRS score.
Statisticalanalysisincludeddescriptivestatistics.Testsfor
correlation and for signiﬁcance of diﬀerences were per-
formed by using SPSS.
3. Results
56 patients (33 male/23 female) with a mean age of 69 years
(min. 41, max. 93) presented with a mean NIHSS score of
16,6. The site of occlusion was internal carotid artery (ICA)/
Carotid T in 17/56 (30%), middle cerebral artery (MCA) in
25/56 (45%), and basilar artery (BA) in 14/56 (25%) cases.
33 (59%) procedures were performed with pCR or CRC as
the only MTE device. The remaining 23 (41%) procedures
were performed with the pCR/CRC in combination with one
or more of the following devices: Penumbra system (8/23),
the Solitairestent (12/23), Enterprisestent (1/23), the Merci
L5 (3/23), the Catch device (2/23), and a microsnare (3/23).
4 patients were treated with IV tPA only (min. 50mg,
max. 72mg) before carrying out mechanical thrombectomy
(MTE). In 16 patients, MTE was preceded by intraarterial
tPA (min. 5mg, max. 40mg), and 17 patients received both
intravenous and intraarterial tPA (min. 21mg, max. 97mg)
(Figure 2). 19 patients were treated with MTE without
thrombolysis.Statistically,nosigniﬁcanteﬀectonrecanaliza-
tion rates nor an increased rate of hemorrhage in connection
with lytics could be observed.
Overall, we achieved a potentially beneﬁcial TICI IIb/III
reperfusion rate of 61,9% and a TIMI II/III reperfusion rateThe Scientiﬁc World Journal 3
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Figure 2: (a) Acute left-sided occlusion of the carotid T; (b) partial recanalization after administration of 20mg intraarterial rtPA; (c)
placement of the pCR 2/4/20 (arrows) in the ACM (M1) distal to the thrombus; (d) recanalization of the carotid T and ACA after retraction
of the pCR with thrombus left in the M1 segment; (e) and (f) TICI 2a (TIMI 2) reperfusion after second passage with the pCR and
administration of 40 mg intraarterial rtPA collectively. The inferior M2 branch remains occluded.
of 85,5% (Figure 5). Regarding the unimodal procedures
with pCR/CRC alone (n = 33), the TICI IIb/III recanalisa-
tion was 54,5% and 84,2% TIMI II/III, respectively, whereas
the multimodal procedures (n = 22) could even yield a
72,8% TICI IIb/III and 86,4% TIMI II/III reperfusion. How-
ever, this diﬀerence did not reach a level of statistical signifi-
cance.
The mean angio-to-reperfusion times (ART) were 74
minutes for pCR/CRC-only procedures (SD ± 54) and 51
minutes for multimodal procedures (SD ± 29) in average.
This diﬀerence is signiﬁcant on a 10% level (P = 0.065,
Mann-Whitney U)( Figure 6). A chronologic analysis of
ART also showed a reduction over time from an average
of 70,5min (SD ± 30,4) for the ﬁrst 10 procedures to 49,4
(SD ± 26,7) for the last 10 (Figure 7). Likewise, we observed
a signiﬁcant shift from mono- to multimodal procedures
during the observation period from 25% for ﬁrst 12 cases to
91,7% for last 12 cases (P = 0,001, χ2) with a simultaneous
increase of potentially beneﬁcial reperfusion results (TICI
IIb/III) from 53,8% to 81,8% referring to the ﬁrst and last
12 procedures.
Clinical improvement after the procedure could be seen
in 54% when evaluated with NIHSS (n = 28) and in 37%
according to the mRS (n = 38). NIHSS improvement was
largely dependent on the vascular territory. It occurred in
73% of MCA recanalizations (n = 15) and in 57,1% of ICA
occlusions (n = 7). Only one patient improved after BA rec-
analization (Figures 3 and 4).
30,4% of the patients (17/56) died during their hospital
stay. These patients had an initial mean NIHSS of 22 (SD ±
12), an ICA/Carotid-T occlusion in 5, an MCA occlusion in
6, and an occlusion of the BA in 6 cases. The mean time4 The Scientiﬁc World Journal
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Figure 3: (a) Acute distal basilar artery occlusion, application of 10mg IA rtPA without visible eﬀect; (b) passage of the thrombus with
guidewire and microcatheter, tip of the basilar artery and both posterior cerebral arteries are open; (c) placement of pCR 2/4/20 in each
P1-segment of the posterior cerebral artery (arrows); (d) simultaneous retraction of the thrombectomy device into the guiding catheter
leads immediately to full (TICI 3) reperfusion (kissing technique).
to ﬁrst reperfusion for these patients was 323 minutes; the
reperfusion result was TICI IIb/III in 10/17 cases and TICI
0-IIa in 7/17 cases.
There were 3 procedural adverse events, each without
clinical consequences referred to a change in NIHSS ≥4
and no device-related adverse event. The rate of SICH after
treatment was 5,5% (3/56).
4. Discussion
Since the ﬁrst promising case reports and in vitro study in
2006 and 2008 [5, 6], this is the ﬁrst study that demonstrates
thefeasibilityandeﬀectivenessofthephenoxsystemaloneor
as a part of a multimodality approach to MTE under clinical
conditions in acute stroke patients.
For the evaluation of our reperfusion results, we decided
to use the more reﬁned TICI classiﬁcation (instead of TIMI)
because of the graduation of the category “partial recanal-
ization” (TICI II) in less or more than 2/3rds reperfusion
of the dependent territory. This diﬀerentiation seemed to be
reasonable with respect to expected patient outcome. Based
onthisconsideration,wesuggestthatreperfusionoflessthan
66% of the dependent territory (TICI IIa) is substantially
less beneﬁcial than ≥66% reperfusion (TICI IIb/III). Hence,
successfule recanalization was deﬁned as a TICI IIb/III
result. However, most likely due to the heterogenity of our
sample and probably due to some lacking outcome data, no
statistical proof for this assumption could be found in this
retrospective study. Nevertheless, many other studies haveThe Scientiﬁc World Journal 5
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Figure 4: Very few DWI lesions in follow-up MRI 24h after symptom onset in pons (white arrows) and in the right thalamus (black arrow)
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Figure 5: The diverging graphs demonstrate the increasing pre-
ponderance of potentially beneﬁcial TICI 2b/3 reperfusion results
(green line) over the frustrating recanalization results (TICI 0/1/2a,
red line) in the time course of the observation period. This
observation is partially attributable to our institutional learning
curve.
already proven that recanalization of the occluded vessel is
associated with better outcome [1–3, 7].
Regarding our sample, especially the patients with MCA
occlusions took advantage of MTE, followed by the patients
with ICA occlusions. No statistically proven clinical beneﬁt
wasseeninpatientswithBAocclusions.Onereasoncouldbe
collateral ﬂow, probably more often present in MCA occlu-
sionsthaninICAorBAocclusions.Anyhow,whenlookingat
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Figure 6: The box plot shows the signiﬁcant (P<0.065, Mann-
Whitney U) shorter angio-to-reperfusion times of multimodal
procedures compared with unimodal procedures.
thepooroutcomedataoftheBAocclusions,oneshouldkeep
in mind that according to previous studies the percentage of
patients that actually died or showed clinical worsening was
much lower than the natural history of this disease [8].
There are some issues when comparing our reperfusion
results with other mechanical thrombectomy studies, mostly
because of the diﬀerent deﬁnitions of a successful recanal-
ization and reperfusion. The Multi Merci Trial has the most6 The Scientiﬁc World Journal
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Figure 7: The scatter plot visualizes 2 interesting observations.
Throughout the observation period, we used increasingly a mul-
timodal recanalization strategy with simultaneously decreasing
reperfusion times.
comparable deﬁnition with similar reperfusion results [1].
Seemingly better reperfusion results are reported for the
Penumbra system [3, 9–11], whereas in these studies a TIMI
II result in the target vessel is already valued as a successful
recanalization. This might be one cause for the relative
lower rate of good clinical outcome (25%) despite the higher
recanalization rate of 81,6% in the penumbra pivotal stroke
study [3].
In the present study, mechanical thrombectomy with the
pCR/CRC yielded TICI IIb/III recanalization in 54,5% (n =
33) when used unimodally and up to 72,8% (n = 22) when
applied in a multimodal manner. Even though this eﬀect did
not reach a level of signiﬁcance, it is remarkable because of
a similar observation made in the Multi Merci Trial with the
newer generation L5 Merci retriever [1]. In this study, TIMI
II/III reperfusion was achieved in 57,3% when the procedure
was done with the Merci retriever exclusively, whereas 69,5%
could be reached when the retriever was combined with
intraarterial tPA or other mechanical devices.
Anotherpositiveeﬀectofthemultimodalapproachcould
be found regarding the procedure times. ART decreased
signiﬁcantly when we pursued an escalative strategy with
rapidchangingofthedeviceafteralimitednumberofunsuc-
cessfulattempts.Anotherinterestingfactisthetrendtowards
shorter ARTs and a shift of the treatment strategy from uni-
to multimodal in the time course of the observation period.
Thus, the reason for shorter procedure times at the end of
the observation period can be both increasing experience
on one hand and the use of a more successful multimodal
recanalization strategy on the other hand.
We had an acceptable low percentage of symptomatic
intracranial hemorrhages (SICH) of 5,5% (3/56) which is
substantially lower than in the PROACT II study and the
Multi Merci Trial where SICH occurred in 10,9% and in
9,8%, respectively [1, 7, 12]. Besides, there was no device-
related complication.
5. Conclusion
The phenox clot retriever pCR and CRC have proven to
be safe and eﬀective tools for mechanical thrombectomy in
acute stroke patients. When used exclusively in a unimodal
manner, successful recanalization could be reached in 54,5%
opposed to 72,8% in the multimodality setting. The escala-
tive strategy showed two major advantages: a higher percent-
age of TICI IIb/III reperfusion rates and shorter angio-to-
reperfusion times. However, these eﬀects are at least partially
attributable to our institutional learning curve. Clinical im-
provement is more frequent in MCA recanalizations than
in BA recanalizations. Despite our escalative strategy, no
increase in the rate of sICH over previous studies and no
adverse events due to the phenox clot retriever could be
observed.
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